162 related articles for article (PubMed ID: 36628991)
1. Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
Kaloyannidis P; Al Zayer M; Al Darweesh M; Al Batran M; Al Garni A; Al Naim A; Al Hashmi H; Kanfar S
Leuk Lymphoma; 2023 Mar; 64(3):742-745. PubMed ID: 36628991
[No Abstract] [Full Text] [Related]
2. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
3. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis.
Zinzani PL; Chen R; Armand P; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Lin J; Nahar A; Balakumaran A; Moskowitz CH
Leuk Lymphoma; 2020 Apr; 61(4):950-954. PubMed ID: 31905294
[No Abstract] [Full Text] [Related]
5. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Howell M; Gibb A; Radford J; Linton K
Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
[No Abstract] [Full Text] [Related]
6. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Br J Haematol; 2020 May; 189(3):e86-e90. PubMed ID: 32048731
[No Abstract] [Full Text] [Related]
7. Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study.
Marouf A; Cottereau AS; Kanoun S; Deschamps P; Meignan M; Franchi P; Sibon D; Antoine C; Gastinne T; Borel C; Hammoud M; Sicard G; Gille R; Cavalieri D; Stamatoullas A; Filliatre-Clement L; Lazarovici J; Chauchet A; Fornecker LM; Amorin S; Rocquet M; Raus N; Burroni B; Rubio MT; Bouscary D; Quittet P; Casasnovas RO; Brice P; Ghesquieres H; Tamburini J; Deau B
Haematologica; 2022 Jul; 107(7):1681-1686. PubMed ID: 34965701
[No Abstract] [Full Text] [Related]
8. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
9. Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children's Oncology Group.
Buhtoiarov IN; Mba NI; Santos CDL; McCarten KM; Metzger ML; Pei Q; Bush R; Baker K; Kelly KM; Cole PD
Pediatr Blood Cancer; 2022 Jun; 69(6):e29649. PubMed ID: 35338689
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
Kort J; Chidiac A; El Sayed R; Massoud R; Nehme R; Bazarbachi A; El-Cheikh J
Leuk Lymphoma; 2020 Jul; 61(7):1732-1735. PubMed ID: 32090673
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
Moretti M; Liberati AM; Rigacci L; Puccini B; Pulsoni A; Gini G; Galieni P; Fabbri A; Cantonetti M; Pavone V; Bolis S; Botto B; Renzi D; Falchi L
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):198-204. PubMed ID: 34690088
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma.
Damlaj M; Abuelgasim KA; Alhejazi A; Alahmari B; Alaskar A; Alzahrani M
Bone Marrow Transplant; 2020 Dec; 55(12):2322-2325. PubMed ID: 32404976
[No Abstract] [Full Text] [Related]
17. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.
Uncu Ulu B; Dal MS; Yönal Hindilerden İ; Akay OM; Mehtap Ö; Büyükkurt N; Hindilerden F; Güneş AK; Yiğenoğlu TN; Başcı S; Kızıl Çakar M; Yanardağ Açık D; Korkmaz S; Ulaş T; Özet G; Ferhanoğlu B; Nalçacı M; Altuntaş F
J Chemother; 2022 May; 34(3):190-198. PubMed ID: 34514960
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma.
Vinti L; Pagliara D; Buffardi S; Di Ruscio V; Stocchi F; Mariggiò E; Parasole R; Di Matteo A; Petruzziello F; Paganelli V; De Vito R; Del Bufalo F; Strocchio L; Locatelli F
Pediatr Blood Cancer; 2022 Apr; 69(4):e29557. PubMed ID: 35107876
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.
Graf SA; Gopal AK
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):151-7. PubMed ID: 25696848
[TBL] [Abstract][Full Text] [Related]
20. Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series.
Broccoli A; Argnani L; Coppola PE; Gentilini M; Bagnato G; Lolli G; Carella M; Nanni L; Morigi A; Casadei B; Pellegrini C; Stefoni V; Zinzani PL
Tumori; 2023 Apr; 109(2):249-252. PubMed ID: 35441544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
